Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03464149
Other study ID # The Longitudinal PTH-Study
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 20, 2018
Est. completion date August 7, 2019

Study information

Verified date June 2020
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main study aim is to quantify the agreement between the analytical results provided by two third generation and two second generation Parathyroid hormone (PTH) assays. The primary comparison will be performed between the second-generation PTH assay"Intact PTH assay" from Siemens Healthcare Diagnostics Inc. and the third-generation PTH assay "biointact (1-84)" from Roche Diagnostics in terms of a Bland-Altman analysis. Several studies have evaluated the correlation between various PTH assays at a single time-point, but no previous study has tested the hypothesis that longitudinal changes in PTH levels, which are important for making treatment decisions, can be monitored by several PTH assays alike. To this aim, the key secondary objective is to analyze the longitudinal variance in PTH over the course of 1 year, using each of two assays of the second and third generations, respectively. Other secondary objectives include determining changes in serum phosphate, serum calcium, fibroblast growth factor 23 (FGF23), with respect to treatment decisions. For clinical applicability of the results to be obtained here, an important goal of the present study will be not to influence treatment decisions, which will remain independent of the study investigators, at the full responsibility of the hemodialysis physicians.

At every quarterly blood draw over the course of one year, the investigators will freeze the serum from 100 patients, and at the end of 4 quarters the investigators will analyze PTH-levels using the following assays: Intact Parathyroid Hormone (Advia Centaur, Siemens Healthcare), PTH-Intact (Cobas, Roche), PTH (1-84) - The agreement between the PTH assays will be analyzed at baseline, as well as at the subsequent quarterly evaluation time-points by Bland-Altman analysis and complemented by Passing-Bablok regression. The longitudinal changes in PTH will be displayed graphically and analyzed by estimating the within-patient variance across time, the between patient variance at each time-point as well as effects on the mean log-PTH level due to course of disease and therapeutic interventions from a linear mixed model.


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date August 7, 2019
Est. primary completion date December 5, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All patients who were undergoing uninterrupted hemodialysis or hemodiafiltration at the Chronic Hemodialysis Unit of the Division of Nephrology and Dialysis, Medical University of Vienna between November 1st, 2017 and December 31st, 2018.

- Existence of residual blood samples from four successive quarterly routine controls

- Age = 18 years

- The test result of the assay must not have any diagnostic value or therapeutic consequence for the patients included in this study.

Exclusion Criteria:

- Death during the observational period (all patients must have lived through the 1-year period and must have all 4 quarterly blood draws performed on them).

- Age <18 years

Study Design


Intervention

Diagnostic Test:
One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)
Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)

Locations

Country Name City State
Austria Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Longitudinal change in PTH levels measured in [pg/ml] PTH levels as measured by the second and third generation assays Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12)
Secondary Longitudinal within-patient change of PTH levels in [pg/ml] Longitudinal within-patient variance of PTH over the course of 1 year, using each of two assays of the second and third generations, respectively. Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12)
Secondary Serum Calcium levels Serum Calcium levels Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12)
Secondary Serum Phosphate levels Serum Phosphate levels as measured by quarterly routine controls Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12)
Secondary Fibroblast growth factor 23 (FGF23 Fibroblast growth factor 23 (FGF23) as measured in quarterly routine controls Timepoints of four consecutive quarterly routine controls per patient (month 1; month 4 ; month 8, month 12)
See also
  Status Clinical Trial Phase
Completed NCT02549417 - Phase 3 Study of KHK7580 Phase 3
Completed NCT02549404 - Phase 3 Study of KHK7580 Phase 3
Not yet recruiting NCT02536287 - Comparison of Total Parathyroidectomy With and Without Autotransplantation Phase 3
Completed NCT02549391 - Phase 3 Study of KHK7580 Phase 2/Phase 3
Active, not recruiting NCT03023748 - Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase 4
Withdrawn NCT01426724 - Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease N/A
Completed NCT01101113 - Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Phase 4
Completed NCT01220050 - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism Phase 2
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00431496 - A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Phase 4
Completed NCT00073710 - Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Phase 4
Completed NCT00117052 - SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism Phase 3
Completed NCT03626948 - SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis Phase 3
Completed NCT01382212 - A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis Phase 3
Completed NCT01224782 - Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) N/A
Completed NCT01219855 - Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) Phase 2/Phase 3
Completed NCT00990704 - Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism Phase 2
Completed NCT00999037 - FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease N/A
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2